Evidence map›Paper›PMID 39185349›Full record

ArticleInternational journal of nanomedicine2024

Combined UTMD-Nanoplatform for the Effective Delivery of Drugs to Treat Renal Cell Carcinoma.

Ting Dai, Qimeihui Wang, Lingyu Zhu, Qiang Luo, Jiayu Yang, Xia Meng, Hui Wang, Zhixia Sun

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ting Dai *Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, People's Republic of China.ORCID 0000-0002-1877-5491
Qimeihui Wang *Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, People's Republic of China.
Lingyu ZhuDepartment of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, People's Republic of China.ORCID 0000-0003-2973-588X
Qiang LuoDepartment of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, People's Republic of China.
Jiayu YangDepartment of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, People's Republic of China.
Xia MengDepartment of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, People's Republic of China.
Hui WangDepartment of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, People's Republic of China.ORCID 0000-0002-1608-3782
Zhixia SunDepartment of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The effective accumulation of nanoparticles (NPs) in the tumour area is an important goals of current nanotechnology research, and a targeted nanoplatform is an effective solution. So we designed a multifunctional sound-sensitive targeted NP that combines a sonosensitizer to enable precisely targeted, deep-penetration sonodynamic therapy (SDT) in combination with multimodal imaging for the diagnosis and monitoring of renal cell carcinoma (RCC). Methods: ZnPP@PP NPs (ZnPP@PLGA- PFP NPs) were prepared via a double emulsion method, and G250 was covalently attached to the NPs shell via the carbon diimide method. Physicochemical property tests were conducted on the ZnPP@G-PP NPs, including tests of particle size, potential distribution, encapsulation efficiency and drug loading capability. We assessed the targeting ability, the production of reactive oxygen species (ROS) and permeability of the NPs in vitro. Moreover, we evaluated the nanoparticle's multimodal imaging capabilities and therapeutic ability against RCC, both in vitro and in vivo. Results: The Znpp@G-PP NPs were successfully constructed, and their general properties showed uniform particle size, negative potential and good stability. The nanoparticles were successfully loaded with ZnPP and connected with G250, showing tumor-specific targeting ability. Under LIFU irradiation, the nanoparticles produced Conclusion: ZnPP@G-PP NPs provide a promising theranostic strategy for RCC and a platform for further research on improving the efficacy of diagnosis and treatment.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsAnimalsAntineoplastic AgentsCell Line, TumorHumansMiceMice, Inbred BALB CMice, NudeNanoparticlesParticle SizePolylactic Acid-Polyglycolic Acid CopolymerReactive Oxygen SpeciesUltrasonic TherapyXenograft Model Antitumor AssaysAntineoplastic AgentsPolylactic Acid-Polyglycolic Acid CopolymerReactive Oxygen Speciesdeep-penetrationmultimodal imagingsonodynamic therapytargeted therapy

Identifiers

PMID39185349
PMCPMC11345023

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.